Selinexor (KPT-330) in Older Patients With Relapsed AML
Status:
Completed
Trial end date:
2018-01-08
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor
given orally versus specified investigator choices (one of three potential salvage
therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except
for AML M3, after one prior therapy only, who have never undergone and who are not currently
eligible for stem cell transplantation and are currently deemed unfit for intensive
chemotherapy.